Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Expected patent protection extends until at least February 2041 for AP-SA02 and about January 4, 2043 for AP-PA02.

Rhea-AI Summary

Armata Pharmaceuticals (ARMP) announced two issued U.S. patents protecting treatment methods using its clinical bacteriophage candidates AP-SA02 and AP-PA02.

Patent No. 12,751,983, issued October 6, 2026, covers treatment of Staphylococcus aureus infections using AP-SA02. Armata expects protection until at least February 2041. Patent No. 12,594,312, issued April 7, 2026, covers treatment of Pseudomonas infections using AP-PA02, with expected protection until about January 4, 2043.

The portfolio now includes 101 issued patents and 60 pending applications across 15 patent families, with nominal expiration dates through 2046. Armata plans to begin a Phase 3 superiority study, designed to test whether AP-SA02 provides better treatment results, in complicated S. aureus bloodstream infections in the second half of 2026.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Armata plans an AP-SA02 Phase 3 superiority study beginning in the second half of 2026.
• Minor pointAP-SA02 treatment-method patent issued October 6, 2026; protection expected until at least February 2041.
• Minor pointAP-PA02 treatment-method patent issued April 7, 2026; protection expected until about January 4, 2043.
• Minor pointGlobal portfolio comprises 101 issued patents, with nominal portfolio expiration dates through 2046.

Negative

• None.

Key Figures

U.S. patents issued: 2 patents AP-SA02 patent protection: Until at least February 2041 AP-PA02 patent protection: Until about January 4, 2043 +2 more

U.S. patents issued

2 patents

Covering AP-SA02 and AP-PA02

AP-SA02 patent protection

Until at least February 2041

U.S. patent

AP-PA02 patent protection

Until about January 4, 2043

U.S. patent; includes 617 days of patent term adjustments

Issued patents in global portfolio

101 patents (15 U.S.; 86 ex-U.S.)

Armata global IP portfolio

Pending patent applications

60 applications (9 U.S.; 51 ex-U.S.)

Armata global IP portfolio

Key Terms

patent term adjustments, patent term extensions, qidp, fast track designation, +1 more

5 terms

patent term adjustments regulatory

"may be eligible for patent term adjustments"

Patent term adjustments are extra days added to the normal statutory patent term to compensate for delays by the patent office in processing a patent application. In the U.S. system they are calculated by rules that measure specific types of office delay (such as missed statutory deadlines or prolonged examination), then subtract any delays caused by the applicant (for example, requests for continued examination, late responses, or extensions); the resulting number of days is added to the 20-year term measured from the patent’s earliest effective filing date. PTAs cannot compensate for certain other statutory delays (such as time spent in secrecy orders) and are subject to administrative review and judicial challenge.

patent term extensions regulatory

"may be eligible for patent term extensions"

An added period of effective life granted to a patent to compensate for time lost while obtaining required regulatory approvals or because of administrative delays, so the patent holder gets extra years of exclusivity beyond the original statutory term. Commonly used in pharmaceuticals and medical devices, these extensions are calculated under specific laws or agency rules, apply only to patents that cover the regulated product or its approved use, and are subject to caps, eligibility criteria and formulae that vary by jurisdiction (for example, separate rules govern extensions for regulatory review delays versus adjustments for patent office processing delays).

qidp regulatory

"Qualified Infectious Disease Product (QIDP) designation"

A QIDP (Qualified Infectious Disease Product) is a regulatory designation for drugs or biologics that treat serious bacterial or fungal infections. It signals faster review and gives additional market protection after approval, like an extra patent-like time window, which can delay competitors — think of it as a temporary “no-competition” zone enforced by the regulator. For investors, QIDP status can speed a product to market and meaningfully enhance revenue potential and valuation.

fast track designation regulatory

"Fast Track designation, and Breakthrough Therapy designation from the FDA"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

cgmp technical

"current Good Manufacturing Practices ("cGMP") manufacturing"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041

LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced issuance of two patents by the United States Patent and Trademark Office ("USPTO") covering its bacteriophage programs, AP-SA02 and AP-PA02. These newly issued U.S. patents support Armata's leadership in bacteriophage therapeutics and specifically, strengthen the intellectual property ("IP") around the AP-SA02 and AP-PA02 programs, which are highly impactful and potential first- and best-in-class therapies. With patent protection extending into at least 2041, Armata's programs are supported by a robust, long-term IP foundation, with additional patents pending.

Dr. Deborah Birx, Chief Executive Officer of Armata, said, "These are two important patents for our Company. Not only do they strengthen our programs in Staphylococcus aureus and Pseudomonas aeruginosa, but they also exemplify our strategy of protecting each phage cocktail that is created using our proprietary phage platform. With the rapidly growing interest in phage-based therapeutics as a potentially improved treatment option against antibiotic-resistant and difficult-to-treat bacterial strains, our intellectual property is increasingly vital to protecting our position as a leader in this promising treatment modality. The issuance of these key patents further reinforces the uniqueness of our bacteriophage programs and our Phase 3-ready candidate, AP-SA02, which is scheduled to enter a superiority study later this year."

Armata's bacteriophage intellectual property portfolio includes 15 patent families with issued or pending claims covering the Company's bacteriophage development programs. With these issuances, the company's global IP portfolio consists of 101 issued patents (15 U.S. and 86 ex-U.S.) and 60 pending patent applications (9 U.S. and 51 ex-U.S.) with nominal expiration dates through 2046.

Details of the newly allowed patents are as follows:

U.S. Patent No. 12,751,983: Bacteriophage Compositions For Treating Staphylococcus Infection

Issued on October 6, 2026, protects methods of treating Staphylococcus aureus infections using its lead product candidate, AP-SA02, which is currently in development for adjunct treatment of complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). The patent is expected to provide patent protection until at least February 2041, and may be eligible for patent term adjustments or patent term extensions affording even later protection.

U.S. Patent No. 12,594,312: Bacteriophage Compositions For Treating Pseudomonas Infection

Issued on April 7, 2026, protects methods of treating Pseudomonas infections using its clinical candidate, AP-PA02, which is in development against various diseases or indications caused by Pseudomonas infections. The patent is expected to provide patent protection until about January 4, 2043 which includes 617 days of patent term adjustments, and this case may be eligible as well for patent term extensions affording even later protection.

About AP-SA02

Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP) designation, Fast Track designation, and Breakthrough Therapy designation from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.

About AP-PA02

Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections due to Pseudomonas aeruginosa in people with cystic fibrosis (CF) and with non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 has shown promising results in two Phase 2 clinical trials to date, SWARM-P.a. (NCT04596319) and Tailwind (NCT05616221).

About Armata Pharmaceuticals, Inc.

Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements

This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:

Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
612660624v.1

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-strengthens-intellectual-property-portfolio-with-two-recent-patent-issuances-in-the-united-states-302900574.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What do Armata's new AP-SA02 and AP-PA02 patents cover?

The patents protect methods of treating bacterial infections using Armata's clinical candidates. Patent No. 12,751,983 covers Staphylococcus aureus infections using AP-SA02, while Patent No. 12,594,312 covers Pseudomonas infections using AP-PA02.

Could Armata's AP-SA02 and AP-PA02 patent protection be extended?

Both patents may be eligible for later protection. The AP-SA02 patent may qualify for patent term adjustments or extensions. The AP-PA02 patent's expected protection until about January 4, 2043 already includes 617 days of patent term adjustments, and it may also qualify for patent term extensions.